Lori Minasian

Lori Minasian

UNVERIFIED PROFILE

Are you Lori Minasian?   Register this Author

Register author
Lori Minasian

Lori Minasian

Publications by authors named "Lori Minasian"

Are you Lori Minasian?   Register this Author

100Publications

2754Reads

18Profile Views

Clinical Outcome Assessments Toolbox for Radiopharmaceuticals.

Front Oncol 2019 10;9:1028. Epub 2019 Oct 10.

Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2019.01028DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6795707PMC
October 2019

Complications and Survivorship Trends After Primary Debulking Surgery for Ovarian Cancer.

J Surg Res 2019 Sep 24;246:34-41. Epub 2019 Sep 24.

Department of Ob/Gyn, Virginia Commonwealth University Medical Center, Richmond, Virginia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jss.2019.08.027DOI Listing
September 2019

A Rare Opportunity: Examining the Experience of a New Institutional Review Board.

J Empir Res Hum Res Ethics 2019 Jul 20;14(3):274-285. Epub 2019 May 20.

1 National Institutes of Health, National Cancer Institute, Rockville, MD, USA.

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1556264619841815
Publisher Site
http://dx.doi.org/10.1177/1556264619841815DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6565466PMC
July 2019

Concordance with BRCA1/2 testing guidelines among women in The Health of Women (HOW) Study.

Breast Cancer Res Treat 2019 Feb 9;173(3):719-726. Epub 2018 Nov 9.

Division of Cancer Control and Population Sciences, National Cancer Institute, 9609 Medical Center Drive, Rockville, MD, 20850, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-018-5035-0
Publisher Site
http://dx.doi.org/10.1007/s10549-018-5035-0DOI Listing
February 2019

Long-Term Effects of Finasteride on Prostate Cancer Mortality.

N Engl J Med 2019 01;380(4):393-394

CHRISTUS Santa Rosa Hospital Medical Center, San Antonio, TX

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1809961DOI Listing
January 2019

Changing Hearts and Minds: Improving Outcomes in Cancer Treatment-Related Cardiotoxicity.

Curr Oncol Rep 2019 01 30;21(1). Epub 2019 Jan 30.

Division of Cancer Prevention, National Cancer Institute, Rockville, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0751-0DOI Listing
January 2019

Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048.

J Clin Oncol 2018 Sep 11:JCO2018788620. Epub 2018 Sep 11.

Ethan Basch, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill; Bryce B. Reeve, Duke Cancer Institute, Duke University Medical Center, Durham, NC; Ethan Basch, Lauren J. Rogak, Mary C. Shaw, Narre Heon, and Martin R. Weiser, Memorial Sloan Kettering Cancer Center, New York, NY; Amylou C. Dueck and Brenda Ginos, Alliance Statistics and Data Center, Mayo Clinic, Scottsdale, AZ; Sandra A. Mitchell, Lori M. Minasian, and Andrea M. Denicoff, National Cancer Institute, Rockville, MD; Jennifer K. Wind, Harvey J. Mamon, and Deborah Schrag, Dana-Farber/Partners CancerCare, Boston, MA; Qian Shi, Garth D. Nelson, and Jeffrey P. Meyers, Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN; George J. Chang, University of Texas MD Anderson Cancer Center, Houston, TX; Tatjana Kolevska, Kaiser Permanente Vallejo Medical Center, Vallejo, CA; and Deborah Watkins Bruner, Emory University, Atlanta, GA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.8620DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209091PMC
September 2018

Longitudinal Trajectory and Characterization of Cancer-Related Cognitive Impairment in a Nationwide Cohort Study.

J Clin Oncol 2018 Sep 21:JCO2018786624. Epub 2018 Sep 21.

Michelle C. Janelsins, Charles E. Heckler, Luke J. Peppone, Supriya G. Mohile, Karen M. Mustian, Annalynn M. Williams, Allison Magnuson, and Gary R. Morrow, James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester; Tim A. Ahles, Memorial Sloan Kettering Cancer Center, New York, NY; Oxana Palesh, Stanford Cancer Center, Stanford, CA; Ann M. O'Mara and Lori M. Minasian, National Cancer Institute (NCI), National Institutes of Health, Rockville, MD; Jodi Geer, Metro Minnesota NCI Community Oncology Research Program (NCORP), Saint Louis Park, MN; Shaker R. Dakhil, Wichita NCORP, Wichita, KS; and Judith O. Hopkins, Southeast Clinical Oncology Research Consortium NCORP, Winston-Salem, NC.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2018.78.6624
Publisher Site
http://dx.doi.org/10.1200/JCO.2018.78.6624DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225503PMC
September 2018

Use of raloxifene and tamoxifen by breast cancer risk level in a Medicare-eligible cohort.

Am J Obstet Gynecol 2018 06 7;218(6):606.e1-606.e9. Epub 2018 Apr 7.

Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajog.2018.03.031DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5970073PMC
June 2018

Hysterectomy-corrected rates of endometrial cancer among women younger than age 50 in the United States.

Cancer Causes Control 2018 05 1;29(4-5):427-433. Epub 2018 Mar 1.

Division of Cancer Control & Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10552-018-1018-zDOI Listing
May 2018

Prevention of cisplatin-induced hearing loss in children: Informing the design of future clinical trials.

Cancer Med 2018 May 30. Epub 2018 May 30.

Division of Hematology, Oncology, and Blood and Bone Marrow Transplantation, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.1563DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6051159PMC
May 2018

Ovarian Cancer Prevention in High-risk Women.

Clin Obstet Gynecol 2017 12;60(4):738-757

*Department of Obstetrics and Gynecology, Virginia Commonwealth University, Richmond, Virginia †Johns Hopkins School of Medicine, Kelly Gynecologic Oncology Service, Baltimore, Maryland ‡Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/GRF.0000000000000318DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920567PMC
December 2017

Outcomes from ovarian cancer screening in the PLCO trial: Histologic heterogeneity impacts detection, overdiagnosis and survival.

Eur J Cancer 2017 12 21;87:182-188. Epub 2017 Nov 21.

Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.10.015DOI Listing
December 2017

Using Delayed Toxicities to Re-evaluate Tolerability in Phase 2 Trials: A Case Example using Bortezomib.

Cancer Invest 2017 Aug 10;35(7):484-489. Epub 2017 Jul 10.

d Herbert Irving Comprehensive Cancer Center, Department of Medicine , Columbia University , New York , NY , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/07357907.2017.1340479DOI Listing
August 2017

Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach.

J Clin Oncol 2017 Jul 11;35(20):2329-2337. Epub 2017 Apr 11.

Goli Samimi, Charlisse F. Caga-anan, Michael Dean, Leah E. Mechanic, Lori M. Minasian, and Mark E. Sherman, National Cancer Institute; Lawrence C. Brody, National Human Genome Research Institute, Bethesda, MD; Marcus Q. Bernardini, Stephanie Lheureux, Patricia A. Shaw, Princess Margaret Cancer Centre, Toronto, Ontario; Janice S. Kwon, University of British Columbia; British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Ian G. Campbell, Paul A. James, Masataka Takenaka, and David D. Bowtell, Peter MacCallum Cancer Centre; David D. Bowtell, University of Melbourne, Melbourne, Victoria; Georgia Chenevix-Trench, QIMR Berghofer Medical Research Institute, Brisbane, Queensland; Michael Friedlander, The Prince of Wales Hospital; Susan J. Ramus, University of New South Wales; Susan J. Ramus and David D. Bowtell, Garvan Institute of Medical Research, Sydney, New South Wales, Australia; Fergus J. Couch, Mayo Clinic, Rochester, MN; Joanne A. de Hullu and Marline G. Harmsen, Radboud University Medical Center, Nijmegen, the Netherlands; Susan M. Domchek and Ronny Drapkin, University of Pennsylvania, Philadelphia; Phuong L. Mai, Magee-Women's Hospital of the University of Pittsburgh Medical Center, Pittsburgh, PA; Heather Spencer Feigelson, Kaiser Permanente Institute for Health Research, Denver, CO; Mia M. Gaudet, American Cancer Society, Atlanta, GA; Karen Hurley and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mark E. Robson, Weill Cornell Medical College, New York, NY; Felicitas Lacbawan, Quest Diagnostics Nichols Institute, San Juan Capistrano; Thomas P. Slavin, City of Hope, Duarte, CA; Evan R. Myers, Duke University Medical Center, Durham, NC; Lisa F. Rezende, FORCE: Facing Our Risk of Cancer Empowered, Tampa; Mark E. Sherman, Mayo Clinic, Jacksonville, FL; and Elizabeth M. Swisher, University of Washington Medical Center, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.3439DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5501360PMC
July 2017

Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers.

Cancer Chemother Pharmacol 2017 Jul 2;80(1):165-175. Epub 2017 Jun 2.

Clinical Pharmacology Program, CCR, National Cancer Institute, NIH, 9000 Rockville Pike, Building 10, Room 5A01, Bethesda, MD, 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-017-3346-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361113PMC
July 2017

Opportunistic salpingectomy: What about the role of the ovary in ovarian cancer?

Cancer 2017 05 23;123(10):1699-1702. Epub 2017 Mar 23.

Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30525DOI Listing
May 2017

Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial.

J Natl Cancer Inst 2016 12 26;108(12). Epub 2016 Aug 26.

SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA (JMU, CT, CMT, PJG, WEB); Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX (IMTJr); Columbia University, New York, NY (JDW, DLH); Fred Hutchinson Cancer Research Center, Seattle, WA (SDR); Division of Cancer Prevention, U.S. National Cancer Institute, Rockville, MD (LMM).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw168DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241895PMC
December 2016

The generalizability of NCI-sponsored clinical trials accrual among women with gynecologic malignancies.

Gynecol Oncol 2016 Dec 30;143(3):611-616. Epub 2016 Sep 30.

Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2016.09.026DOI Listing
December 2016

Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials.

J Clin Oncol 2016 09 20;34(25):3014-22. Epub 2016 Jun 20.

Dawn L. Hershman, Jason D. Wright, and Danielle Awad, Columbia University Medical Center, New York, NY; Cathee Till, Scott D. Ramsey, and Joseph Unger, Fred Hutchinson Cancer Research Center; William E. Barlow, University of Washington, Seattle, WA; and Lori M. Minasian, National Cancer Institute, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.66.2346DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5012713PMC
September 2016

Effect of long-term vitamin E and selenium supplementation on urine F2-isoprostanes, a biomarker of oxidative stress.

Free Radic Biol Med 2016 06 22;95:349-56. Epub 2016 Mar 22.

Division of Nutritional Sciences, Cornell University, 209 Savage Hall, Ithaca, NY 14853, USA; Department of Healthcare Policy and Research, Division of Biostatistics and Epidemiology, Weill Cornell Medical College, New York, NY, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.freeradbiomed.2016.03.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4867301PMC
June 2016

The End of the Hysterectomy Epidemic and Endometrial Cancer Incidence: What Are the Unintended Consequences of Declining Hysterectomy Rates?

Front Oncol 2016 14;6:89. Epub 2016 Apr 14.

Division of Cancer Control and Population Sciences, National Cancer Institute , Bethesda, MD , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2016.00089DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830827PMC
May 2016

Reducing Overtreatment in Gynecologic Oncology: The Case for Less in Endometrial and Ovarian Cancer.

Front Oncol 2016 9;6:118. Epub 2016 May 9.

The Division of Cancer Prevention, The National Cancer Institute, National Institutes of Health , Bethesda, MD , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2016.00118DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4860790PMC
May 2016

Case Example of Dose Optimization Using Data From Bortezomib Dose-Finding Clinical Trials.

J Clin Oncol 2016 Apr 29;34(12):1395-401. Epub 2016 Feb 29.

Shing M. Lee, Daniel Backenroth, Ying Kuen Ken Cheung, and Dawn L. Hershman, Columbia University, New York, NY; Diana Vulih and Barry Anderson, Theradex Systems, Princeton, NJ; and Percy Ivy and Lori Minasian, National Cancer Institute, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.66.0662DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070578PMC
April 2016

Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma.

Cancer 2016 Jan 6;122(1):124-30. Epub 2015 Oct 6.

Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29728DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602387PMC
January 2016

Recommendations for Obesity Clinical Trials in Cancer Survivors: American Society of Clinical Oncology Statement.

J Clin Oncol 2015 Nov 31;33(33):3961-7. Epub 2015 Aug 31.

Jennifer A. Ligibel and Elizabeth S. Frank, Dana-Farber Cancer Institute, Boston, MA; Catherine M. Alfano, Elvan C. Daniels, and Kevin D. Stein, American Cancer Society, Atlanta, GA; Dawn Hershman, Columbia University; Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; Rachel M. Ballard, National Institutes of Health; Worta McCaskill-Stevens and Lori M. Minasian, National Cancer Institute, Bethesda, MD; Suanna S. Bruinooge and Laura A. Levit, American Society of Clinical Oncology, Alexandria, VA; Kerry S. Courneya, University of Alberta, Edmonton, Alberta; Pamela J. Goodwin, University of Toronto, Mount Sinai Hospital, Toronto, Ontario, Canada; Wendy Demark-Wahnefried, University of Alabama at Birmingham, Birmingham, AL; Melinda L. Irwin, Yale School of Public Health, New Haven, CT; Mark A. O'Rourke, Greenville Hospital System, Greenville, SC; John P. Pierce, University of California San Diego Moores Cancer Center, San Diego, CA; and Cynthia A. Thomson, University of Arizona, Tucson, AZ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.1440DOI Listing
November 2015

Ongoing Use of Data and Specimens From National Cancer Institute-Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program.

Semin Oncol 2015 Oct 10;42(5):748-63. Epub 2015 Jul 10.

Department of Human Oncology, Pittsburgh Campus of Temple University School of Medicine, Pittsburgh, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2015.07.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4593316PMC
October 2015

Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927.

J Clin Oncol 2015 Jun 4;33(17):1910-7. Epub 2015 May 4.

Dawn L. Hershman, Katherine D. Crew, Danielle Awad, and Heather Greenlee, Columbia University Medical Center, New York, NY; Joseph M. Unger, Danika L. Lew, and Cathee Till, Southwest Oncology Group Statistical Center; Joseph M. Unger, Julie Gralow, Danika L. Lew, Cathee Till, and Carol M. Moinpour, Fred Hutchinson Cancer Research Center, Seattle, WA; Shaker R. Dakhil, Cancer Center of Kansas, Wichita, KS; Lori M. Minasian, National Cancer Institute, Bethesda, MD; James L. Wade III, Central Illinois Community Clinical Oncology Program/Cancer Care Specialists of Central Illinois, Decatur, IL; and Frank L. Meyskens, University of California at Irvine, Chao Family Comprehensive Cancer Center, Orange, CA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2014.59.5595
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.59.5595DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451174PMC
June 2015

Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.

N Engl J Med 2015 Mar;372(10):923-32

From the Cleveland Clinic Foundation, Cleveland (H.C.F.M.); SWOG Cancer Research Group Statistical Center, Fred Hutchinson Cancer Research Center (J.M.U., W.E.B.), and Seattle Cancer Care Alliance and University of Washington (J.G.) - all in Seattle; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC (K.-A.P., P.A.F.), Australia and New Zealand Breast Cancer Trials Group (ANZBCTG) (K.-A.P., P.A.F., J.F.F.), Calvary Mater Hospital, Newcastle, NSW (F.B., J.M.L., J.F.F.), and University of Sydney, Sydney (F.B.) - all in Australia; International Breast Cancer Study Group (IBCSG), Bern, Switzerland (K.-A.P., P.A.F.); National Institute of Oncology, Budapest, Hungary (E.H.); Auckland Regional Cancer and Blood Service, Auckland, New Zealand (D.P.); Fox Chase Cancer Center, Philadelphia (L.J.G.); Instituto de Enfermedades Neoplasicas (H.L.G.) and Oncosalud SAC (C.S.V.), Lima, Peru; Dana-Farber Cancer Institute (A.H.P., R.D.G.) and IBCSG Statistical Center (R.D.G.) - both in Boston; Wichita Community Clinical Oncology Program, Wichita (S.R.D.), and University of Kansas, Westwood (C.J.F.) - both in Kansas; University of Southern California Norris Cancer Center, Los Angeles (A.A.G.), the Angeles Clinic and Research Institute, Santa Monica (S.M.), and University of California at Irvine Chao Family Comprehensive Cancer Center, Orange (F.L.M) - all in California; National Cancer Institute, Division of Cancer Prevention, Bethesda, MD (L.M.); M.D. Anderson Cancer Center, Houston (G.N.H.); and Loyola University Medical Center, Cardinal Bernardin Cancer Center, Maywood, IL (K.S.A.).

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/obgynsurvey/2015/06000/Gosereli
Web Search
http://www.nejm.org/doi/abs/10.1056/NEJMoa1413204
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1413204DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405231PMC
March 2015

Multilevel modeling and value of information in clinical trial decision support.

BMC Syst Biol 2014 Dec 24;8. Epub 2014 Dec 24.

Computer Science and Artificial Intelligence Laboratory and Program in Computational and Systems Biology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12918-014-0140-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4304628PMC
December 2014

Organizational and physician factors associated with patient enrollment in cancer clinical trials.

Clin Trials 2014 Oct 5;11(5):565-75. Epub 2014 Jun 5.

Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1740774514536000DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4156916PMC
October 2014

Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199.

J Clin Oncol 2014 Oct 8;32(29):3275-83. Epub 2014 Sep 8.

Mark E. Sherman, Phuong L. Mai, Lori Minasian, and Mark H. Greene, National Cancer Institute, Rockville; Olga B. Ioffe, University of Maryland Medical Center; Brigitte M. Ronnett, Johns Hopkins Medical Institutions, Baltimore; Chad A. Hamilton, Walter Reed National Military Medical Center, Bethesda, MD; Marion Piedmonte, Roswell Park Cancer Institute, Buffalo; Stephanie V. Blank, New York University School of Medicine; Noah D. Kauff, Memorial Sloan Kettering Cancer Center; New York, NY; Linda Van Le, University of North Carolina at Chapel Hill, Chapel Hill, NC; Iouri Ivanov, Columbus Cancer Council, Columbus, OH; Maria C. Bell, Sanford University of South Dakota Medical Center, Sioux Falls, SD; Paul DiSilvestro, Women and Infants Hospital, Providence, RI; Krishnansu S. Tewari, University of California Medical Center Irvine, Orange, CA; Katie Wakeley, Tufts University; Steven J. Skates, Massachusetts General Hospital, Boston, MA; S. Diane Yamada, University of Chicago, Chicago; Gustavo Rodriguez, North Shore University Health System, Evanston, IL; David S. Alberts, University of Arizona Cancer Center, Tucson, AZ; Joan L. Walker, University of Oklahoma, Oklahoma City, OK; and Karen Lu, MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.54.1987DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4178524PMC
October 2014

Cancer treatment-related cardiotoxicity: current state of knowledge and future research priorities.

J Natl Cancer Inst 2014 Sep 10;106(9). Epub 2014 Sep 10.

Division of Cancer Control and Population Sciences (NS, AF) and Division of Cancer Prevention (JB, LM) and Division of Cancer Treatment and Diagnosis (MD), National Cancer Institute, Rockville, MD; Division of Cardiovascular Sciences, National Heart, Lung and Blood Institute, Bethesda, MD (BA, PDN); Cancer Center, MetroHealth Medical Center and Casewestern Reserve University, Cleveland, OH (JB); Vanderbilt Heart and Vascular Institute, Vanderbilt University School of Medicine, Nashville, TN (TF); Mary Babb Randolph Cancer Center, West Virginia University (SCR), Morgantown, WV.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju232DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176042PMC
September 2014

Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).

J Natl Cancer Inst 2014 Sep 29;106(9). Epub 2014 Sep 29.

: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC (EB, BBR, AVB); Department of Epidemiology and Biostatistics, Health Outcomes Research Group (EB, LS, LR) and Department of Psychiatry and Behavioral Sciences (JH, TMA), Memorial Sloan Kettering Cancer Center, New York, NY; Outcomes Research Branch, Applied Research Program, Division of Cancer Control and Population Sciences (SAM, SBC), Division of Cancer Prevention (LMM), NCTN Clinical Trials Operations, Cancer Therapy Evaluation Program (AD), Community Oncology and Prevention Trials Research Group, Division of Cancer Prevention (AMO, DSG, JK), and Investigational Drug Branch, Cancer Therapy Evaluation Program (AC), National Cancer institute, Bethesda, MD;Division of Health Sciences Research, College of Medicine, Mayo Clinic - Arizona, Scottsdale, AZ (ACD); Department of Symptom Research, Division of Internal Medicine, The University of Texas Anderson Cancer Center, Houston, TX (TRM, CSC); Patient Advocate, New York, NY (DBP); Department of Medicine, Duke Center for Learning HealthCare, Duke Cancer Research Program, Duke University, Durham, NC (APA); Nell Hodgson Woodruff School of Nursing, Winship Cancer Institute of Emory University, Emory University, Atlanta, GA (DWB); Mayo Clinic - Rochester, Rochester, MN (JAS); SemanticBits LLC, Herndon, VA (RC, PB); Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA (AB); Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (DS).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju244DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4200059PMC
September 2014

Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials.

J Natl Cancer Inst 2014 Jul 8;106(7). Epub 2014 Jul 8.

Affiliations of authors: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC (BBR, EB); Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD (SAM); Division of Cancer Prevention, National Cancer Institute, Bethesda, MD (LMM and AMO); Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (AMD); Division of Health Sciences Research, Mayo Clinic, Scottsdale, AZ (ACD); Feinberg School of Medicine, Northwestern University, Chicago, IL (DC); Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, GA (CMR, DWB); Department of General Oncology, MD Anderson Cancer Center, Houston, TX (MJF); Mayo Clinic Breast SPORE, Rochester, MN (CCh); Department of Psychological Research, The Netherlands Cancer Institute, Amsterdam, The Netherlands (NKA); Quality of Life Department, European Organization for the Research and Treatment of Cancer, Brussels, Belgium (CCo).

View Article

Download full-text PDF

Source
http://jnci.oxfordjournals.org/content/106/7/dju132.full.pdf
Web Search
http://www.cancer.gov/about-nci/organization/ccct/steering-c
Web Search
http://www.cancer.gov/about-nci/organization/ccct/steering-c
Web Search
http://jnci.oxfordjournals.org/cgi/doi/10.1093/jnci/dju129
Publisher Site
http://dx.doi.org/10.1093/jnci/dju129DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4110472PMC
July 2014

Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.

J Natl Cancer Inst 2014 Jun 19;106(6):dju089. Epub 2014 May 19.

Affiliations of authors: Medical Oncology Branch, Center for Cancer Research (J-ML, JLH, CMA, AMN, LM, JAZ, MY, NG, TMS, WDF, NA, ECK), National Clinical Target Validation Laboratory, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research (JJ), Center for Interventional Oncology, Radiology, and Imaging Sciences, Clinical Center and National Cancer Institute (BJW), and Division of Cancer Treatment and Diagnosis, National Cancer Institute (JD), National Institutes of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju089DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049120PMC
June 2014

The business case for provider participation in clinical trials research: an application to the National Cancer Institute's community clinical oncology program.

Health Care Manage Rev 2013 Oct-Dec;38(4):284-94

Paula H. Song, PhD, is Assistant Professor, Division of Health Services Management and Policy, College of Public Health, The Ohio State University, Columbus. E-mail: Kristin L. Reiter, PhD, is Associate Professor, Department of Health Policy and Management, The University of North Carolina at Chapel Hill. E-mail: Bryan J. Weiner, PhD, is Professor, Department of Health Policy and Management, The University of North Carolina at Chapel Hill. E-mail: Lori Minasian, MD, is Chief, Community Oncology and Prevention Trials Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland. E-mail: Ann Scheck McAlearney, ScD, is Professor, Department of Family Medicine, College of Medicine, and Professor, Division of Health Services Management and Policy, College of Public Health, The Ohio State University, Columbus. E-mail:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/HMR.0b013e31827292fcDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3594627PMC
May 2014

Phase III prostate cancer chemoprevention trials.

Recent Results Cancer Res 2014 ;202:73-7

Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-642-45195-9_9DOI Listing
May 2014

Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk.

J Natl Cancer Inst 2014 Mar 22;106(3):djt456. Epub 2014 Feb 22.

Affiliations of authors: Cancer Prevention Program (ARK) and SWOG Statistical Center (AKD, CMT, PJG), Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Epidemiology (ARK, GEG) and Department of Environmental Health (GEG), University of Washington, Seattle, WA; University of Missouri, Research Reactor Center, Columbia, MO (JSM); Harry S. Truman Memorial Veterans Hospital, Columbia, MO (JSM); Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX (IMT); Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA (FLM); Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD (LMM, HLP); Moores Cancer Center, University of California San Diego, San Diego, CA (SML); Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH (EAK).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djt456DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3975165PMC
March 2014

Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial.

J Natl Cancer Inst 2013 Aug 10;105(15):1132-41. Epub 2013 Jul 10.

Department of Internal Medicine, Division of Cancer Prevention and Control, The Ohio State University College of Medicine, Columbus, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djt174DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3735464PMC
August 2013

Long-term survival of participants in the prostate cancer prevention trial.

N Engl J Med 2013 Aug;369(7):603-10

University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1215932DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4141537PMC
August 2013

A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment.

Support Care Cancer 2013 Jun 12;21(6):1525-50. Epub 2013 Jan 12.

Nell Hodgson Woodruff School of Nursing, Emory University, 1520 Clifton Rd, NE #254, Atlanta, GA 30322, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00520-012-1688-0
Publisher Site
http://dx.doi.org/10.1007/s00520-012-1688-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4299699PMC
June 2013

Achieving high cancer control trial enrollment in the community setting: an analysis of the Community Clinical Oncology Program.

Contemp Clin Trials 2013 Mar 5;34(2):320-5. Epub 2013 Jan 5.

Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, NC 27599-7411, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cct.2012.12.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3594576PMC
March 2013

Challenges and facilitators of community clinical oncology program participation: a qualitative study.

J Healthc Manag 2013 Jan-Feb;58(1):29-44; discussion 45-6

Department of Family Medicine, College of Medicine, The Ohio State University, Columbus, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763953PMC
March 2013

Effect of state-mandated insurance coverage on accrual to community cancer clinical trials.

Contemp Clin Trials 2012 Sep 8;33(5):933-41. Epub 2012 Jun 8.

Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, Chapel Hill, NC 27599-7411, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cct.2012.06.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3408810PMC
September 2012

Organizational designs for achieving high treatment trial enrollment: a fuzzy-set analysis of the community clinical oncology program.

J Oncol Pract 2012 Sep 1;8(5):287-91. Epub 2012 May 1.

University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7590, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2011.000507DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3439228PMC
September 2012

Accrual to clinical trials: let's look at the physicians.

J Natl Cancer Inst 2011 Mar 11;103(5):357-8. Epub 2011 Feb 11.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djr018DOI Listing
March 2011